Note 11 - Quarterly Financial Data (Unaudited) (Detail) - Summary of the quarterly consolidated results of operations: (USD $)	12 Months Ended
	Dec. 31, 2012	Dec. 31, 2011	Dec. 31, 2010
Revenues	$ 3,570,710	$ 8,790,209	$ 15,331,567
Loss from Operations	(30,046,606)	(25,105,171)	(10,737,198)
Net Income (Loss)	(22,414,640)	(5,229,725)	(26,671,857)
Net Income (Loss) Attributable to Cleveland BioLabs, Inc.	(18,234,142)	(4,013,670)	(26,366,045)
Weighted Average Shares Outstanding, Diluted (in Shares)	37,388,847	32,561,743	26,184,773
March 31 [Member]
Revenues	931,397	2,473,982
Loss from Operations	(7,481,875)	(5,112,153)
Net Income (Loss)	(6,398,894)	(5,745,366)
Net Income (Loss) Attributable to Cleveland BioLabs, Inc.	(5,387,146)	(5,499,059)
Basic Earnings (Loss) Per Share Available for Common Shareholders	(0.15)	(0.19)
Fully Diluted Earnings (Loss) Per Share Available for Common Shareholders	(0.15)	(0.19)
Weighted Average Shares Outstanding, Basic (in Shares)	35,657,563	29,110,979
Weighted Average Shares Outstanding, Diluted (in Shares)	35,657,563	29,110,979
June 30 [Member]
Revenues	258,237	569,049
Loss from Operations	(9,161,724)	(6,627,596)
Net Income (Loss)	(5,906,870)	11,130,148
Net Income (Loss) Attributable to Cleveland BioLabs, Inc.	(5,078,684)	11,368,224
Basic Earnings (Loss) Per Share Available for Common Shareholders	(0.14)	0.38
Fully Diluted Earnings (Loss) Per Share Available for Common Shareholders	(0.14)	0.30
Weighted Average Shares Outstanding, Basic (in Shares)	35,745,675	30,033,049
Weighted Average Shares Outstanding, Diluted (in Shares)	35,745,675	37,588,006
September 30 [Member]
Revenues	219,575	3,801,267
Loss from Operations	(7,841,541)	(6,961,324)
Net Income (Loss)	(12,315,676)	(2,878,554)
Net Income (Loss) Attributable to Cleveland BioLabs, Inc.	(10,877,836)	(2,691,341)
Basic Earnings (Loss) Per Share Available for Common Shareholders	(0.30)	(0.08)
Fully Diluted Earnings (Loss) Per Share Available for Common Shareholders	(0.30)	(0.08)
Weighted Average Shares Outstanding, Basic (in Shares)	35,879,245	35,447,032
Weighted Average Shares Outstanding, Diluted (in Shares)	35,879,245	35,447,032
December 31 [Member]
Revenues	2,161,501	1,945,911
Loss from Operations	(5,561,466)	(6,404,098)
Net Income (Loss)	2,206,800	(7,735,953)
Net Income (Loss) Attributable to Cleveland BioLabs, Inc.	3,109,524	(7,191,494)
Basic Earnings (Loss) Per Share Available for Common Shareholders	0.07	(0.20)
Fully Diluted Earnings (Loss) Per Share Available for Common Shareholders	$ 0.07	$ (0.20)
Weighted Average Shares Outstanding, Basic (in Shares)	42,236,226	35,553,413
Weighted Average Shares Outstanding, Diluted (in Shares)	42,565,945	35,553,413